Composition and methods for MRNA vaccines against novel omicron coronavirus infections
US12280104B2 · kind B2 · utility
0Cited by
1References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 31, 2023 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | Oct 31, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/20034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from an Omicron variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.